Use of snus during pregnancy is not without risk

The use of snus cannot be recommended as an alternative to smoking for pregnant women who have difficulty giving up cigarettes.

Smoking during pregnancy increases the risk of a number of pregnancy complications. The use of snus has increased among young Norwegian women, whereas the number of smokers is declining. Can snus be recommended to pregnant women as an alternative to smoking?

Snus is harmful, it maintains and intensifies addiction, and has no scientifically documented effect as a method for breaking smoking habits. A Swedish review article published in the Läkartidningen in 2011 (1) shows that snus use during pregnancy is more harmful than has been assumed. We have therefore reviewed all the three main studies referred to in the article, which are all based on data from the Swedish medical birth registry.

The first Swedish follow-up study was published in 2003, and included more than 23,000 women who either used snus, smoked, or did not use any forms of tobacco (2). The study showed that snus use increased the risk of premature birth and preeclampsia. Premature delivery was nearly twice as common among snus users as among the non-users of tobacco. In 2010, diabetes. Certain additional factors, such as alcohol consumption, use of other drugs and conditions in the home, are absent from the studies. The fact that the pregnant women were asked about their use of tobacco at an early stage of their pregnancy means that those who started or quit smoking at a later time were not registered, and this can be assumed to have reduced the differences between the snus users on the one hand and the smokers and the non-users on the other.

On the other hand: If we have only one opportunity to inquire about snus use, it is methodologically best to do so at an early stage of the pregnancy. It would have been even better to analyse only those whom we are certain have used snus during their entire pregnancy. Most likely, the registered harmful effects would then have been higher than the studies indicate. Presumably, snus use is similar to smoking in this respect: Those who do not quit when the pregnancy is recognised will fail to do so altogether. Assistance for smoking cessation at the first ultrasound examination will be too late.

We regard the Swedish studies to be of sufficient methodological quality to provide a basis for warning that snus use during pregnancy results in a heightened risk of stillbirth and premature birth, and that it will have a negative effect on birth weight.

Snus use during pregnancy is discouraged
All women should receive the information that snus use during pregnancy entails a risk similar to the risk exposure from smoking. We believe that it is indefensible to recommend the use of snus as an alternative to smoking for pregnant women.

There are only very few studies available on the use of nicotine substitutes during pregnancy (6–8). Thus, we have little knowledge about the effects of and safety considerations for the use of such drugs during this period. We will nevertheless claim that nicotine replacements are preferable to snus use and smoking for those who are unable to break their nicotine dependency. With a normal use of nicotine substitutes, the nicotine dose ingested by the foetus can be assumed to be lower than if the mother uses snus. Furthermore, snus and tobacco smoke contain several other toxic and harmful substances. If nicotine dependency is the problem, the most transparent solution will be counselling accompanied by nicotine substitutes, which do not contain the carcinogens and other toxic substances found in tobacco. However, the women should be counselled about possible harmful short- and long-term effects, and advised that the effects of the use of nicotine substitutes during pregnancy are little known.

A particular responsibility rests on those who recommend the use of a product that may have harmful effects. In pregnancy care, strong emphasis should be placed on motivational treatment and close follow-up to help patients break their cigarette and snus habits – and nicotine substitutes must be used only as a last resort. Most pregnant women will be motivated to avoid the use of tobacco once they receive systematic information on the possible consequences. Midwives and GPs have an important role to play in this regard.

Maja-Lisa Løchen
maja-lisa.lochen@uit.no
Department of Community Medicine
University of Tromsø

Svein Høegh Henrichsen
Langbelgen Medical Centre, Oslo

Tom K. Grimsrud
The Cancer Registry

Turid Lingaas Holmen
Department of Public Health and General Practice
Norwegian University of Science and Technology

Frode Gallefoss
Department of Pulmonary Medicine
Sørlandet Hospital, Kristiansand

Maja-Lisa Løchen [born 1954] is an MD, PhD, and specialist in cardiology. She is Professor of Preventive Medicine at the University of Tromsø and Senior Consultant at the Department of Cardiology, University Hospital of North Norway. The author has completed the ICMJE form and declares no conflicts of interest.
Svein Høegh Henrichsen (born 1952) is an MD and a specialist in family medicine and GP at the Langbølgen Medical Centre in Oslo, and is the leader of the reference group for asthma and COPD under the Norwegian Association of General Practitioners. He is currently working as Senior Adviser in the Department of Public Health, Norwegian Directorate of Health. The author has completed the ICMJE form and declares no conflicts of interest.

Tom Kristian Grimsrud (born 1955) is an MD, PhD, and specialist in occupational medicine. He is a researcher/epidemiologist in the field of occupational and environmentally related cancer in the Research Department, The Norwegian Cancer Registry, Oslo. The author has completed the ICMJE form and declares the following conflict of interest: He is a member of the National Council on Tobacco and Health, and has received compensation for attending meetings.

Turid Lingaas Holmen (born 1947) is an MD, PhD, specialist in paediatrics and Professor of Youth Medicine and Epidemiology at the HUNT research centre, Department of Public Health and General Practice, Norwegian University of Science and Technology. The author has completed the ICMJE form and declares no conflicts of interest.

Frode Gallefoss (born 1956) is a specialist in internal medicine. He is a Senior Consultant at the Department of Pulmonary Medicine Sørlandet Hospital, Kristiansand, and Professor at the Department of Internal Medicine, University of Bergen. The author has completed the ICMJE form and declares no conflicts of interest.

References

Received 20 February 2012, approved 8 March 2012. Medical editor: Petter Gjersvik.